Semaglutide

CAS No.: 910463-68-2

Semaglutide Chemical Structure

Molecular formula: C₁₈₇H₂₉₁N₄₅O₅₉

Molecular weight: 4113. 5775

Patent period: compound: 2026; composition: 2029

Injection (type 2 diabetes, ozempic) : 1. 5 mL, 3 mL

Oral tablets (type 2 diabetes, rybelsus) : 3 mg, 7 mg, 14 mg, once daily

Injection (weight loss, wegovy) : 2.4 mg/0. 75 mL

Get in touch Download

Products are for laboratory research use only. Not for human use. We do not sell to patients.

Biological Activity

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of semaglutide-induced rodent thyroid Ccell tumors has not been determined.

There are currently three FDA-approved semaglutide products:

__ Ozempic

__ Rybelsus

__ Wegovy

Chemical Properties

ACTIONS	Agonist
CAS NO.	910463-68-2
FORMULA	C₁₈₇H₂₉₁N₄₅O₅₉
M.WT	4113. 64
STORAGE	The shelf life of the drug product is 36 months at 5℃, and the in-use shelf life is 56 days at 5℃ to 30℃ after initial use.

Online Inquiry

Diabetes

Chinese diabetic people may have a total of 143 million people, accounting for 23%of the global patients with diabetes. It is the country with the most diabetic patients in the world. Among them, type II diabetes account for about 90%of the number of diabetes, and type I diabetes and gestational diabetes account for about 9 ~ 10%.

Other Drug Peptide More+

Tirzepatide new

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined .
Semaglutide new

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of semaglutide-induced rodent thyroid Ccell tumors has not been determined.
Retatrutide new

Retarutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR) , glucose-dependent insulin-promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) . It is a peptide composed of about 40 amino acids and contains double targets in its sequence. Retarutide inhibited human GCGR, GIPR and GLP-1R with EC50 values of 5. 79, 0. 0643 and 0. 775nM, respectively. Retarutide can be used for obesity research.
Cagrilintide new

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.
Linaclotide new

Linaclotide is a potent and selective guanylate cyclase C agonist; Developed for the treatment of constipation-type irritable bowel syndrome (IBS-C) and chronic constipation.

Product Catalog

Semaglutide

GUIZHOU MTPEPTIDES BIOTECHNOLOGY CO., LTD